Tag: Janssen

September 4, 2019 Off

European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union

By BusinessWire

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.